Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 2 results

ea0081p333 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

REAL Life study of SEMaglutide in Patients with Type 2 diabetes in SPain (REALSEM-SP): Retrospective clinical study on the efficacy, adherence, and safety with Semaglutide

Cardenas Salas Jersy Jair , Poyatos Roberto Miguel Sierra , Luiza Luca Bogdana , Sanchez Lechuga Begona , Modrono Mostoles Naiara , Montoya Alvarez Teresae , GoMez Montes Maria De La Paz , Sanchez-Lopez Raquel , Casado Carlos , Vazquez Martinez Clotilde

Introduction: Real-world data on glucose and weight control effectiveness in patients with Type 2 diabetes mellitus (T2DM) on treatment with semaglutide is scarce. We aim to assess it in a cohort of patients from a real-world setting in Spain.Materials and methods: We identified 830 patients with T2DM that were prescribed Semaglutide once-weekly since May 2019 to December 2020, in 4 hospitals in Madrid-Spain. At 6±3 months, 435 GPL1-naïve and 3...
0 shares

ea0070aep462 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Effects of semaglutide on glycemic control and body composition in patients with type 2 diabetes mellitus and obesity in a real life setting in spain

luiza luca Bogdana , Miguel Sierra Poyatos Roberto , Cardenas Jersy , Sanchez Gomez Nancy , Jesus Silva Rodriguez Maria , Modroño Mostoles Naiara , Montoya Alvarez Teresa , Sanchez Lopez Raquel , Cruces Vega Eva , Estrella Alicia , Barrio Pilar , Sanchez Lechuga Begoña , Gonzalo Montesinos Irene , Jose De la Cruz Fernandez Maria , Perez Alvarez Enrique , Vazquez Martinez Clotilde

Introduction: Semaglutide is a GLP1 receptor agonist (GLP1RA) recently approved in Spain for the treatment of Type 2 Diabetes (T2D) and the National Health Service finances it for patients with T2D and body mass index (BMI) > 30 with a poor metabolic control with metformin.Objectives: Evaluate the effects of Semaglutide on glycemic control and body composition in patients with T2D (PwT2D) and obesity after 6 months of use in a real life setting.<...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more